ATLAS VENTURE

Thesis

Atlas Venture is an early-stage venture capital firm dedicated to building and investing in biotechnology companies. Their core investment thesis is to translate groundbreaking science into life-changing medicines, employing a seed-led investment model that prioritizes a science-first, patient-centric, and collaborative approach. They actively seek entrepreneurs with deep expertise in research, business, and clinical development to establish pioneering biotech companies. The firm's strategic framework involves a four-step process: discover, derisk, shape, and strengthen, with the ultimate goal of bringing novel therapeutic science from the laboratory to the market. Atlas Venture focuses on a wide array of sectors within biotechnology, including life sciences, drug discovery, therapeutics, gene therapy, precision oncology, RNA-modifying proteins, cell therapy, oncology, autoimmunity, novel modality, hematology, ophthalmology, and anti-infectives. Their primary investment stage preference is seed and early-stage, with capabilities for Series A follow-on investments. Geographically, their focus is primarily North America, with a significant concentration in Cambridge, Massachusetts. Their strategy involves venture creation, incubator/co-founding activities, and a long-term partnership approach, often taking active operational involvement and board seats. Atlas Venture has raised substantial capital, including $450 million for its fourteenth fund in December 2024, $400 million for Opportunity Fund III in September 2025, and $300 million for Opportunity Fund II in September 2021. Their reported portfolio value was $790,032,316 USD, with an estimated total AUM of $2.4 billion across six funds. For seed-stage investments, the typical check size ranges from $500,000 to $1,000,000, with overall investments in early-stage companies ranging fr

Related lists

• Seed investors based in Cambridge, MA
• Series A investors based in Cambridge, MA
• Series C+ investors based in Cambridge, MA